When the UTI Keeps Coming Back

The second one arrives two weeks after the first was treated. That pattern usually means something specific, and it is rarely the thing families get told.

Why does she keep getting UTIs?

Often she is not getting a new infection each time. She is carrying bacteria that keep being found again, and each finding gets treated.

Bacteria colonize the bladder the way they colonize skin and gut. In women over sixty living at home, roughly six to ten percent carry them. In long-term care the figure is between twenty-five and fifty percent. With a long-term indwelling catheter it is essentially everyone.

Run the arithmetic. If half the residents on a floor would grow bacteria on any given day, then a resident who gets tested every time she seems off will produce a positive culture about half the time by chance alone. Test her four times in a year and you can generate four "urinary tract infections" out of one unchanging state.

The clinical definition of a recurrent UTI is two episodes in six months or three in twelve. That definition assumes each episode was a real infection — bacteria plus symptoms coming from the urinary tract, or fever, or signs of systemic illness. A string of positive cultures is not the same thing, and the difference decides whether any of the standard prevention advice applies to her at all.

Is a second one two weeks later the same infection or a new one?

The gap between them is a real clue, and it is the single most useful thing you can report.

A caregiver put the pattern plainly: "A UTI the dr treated. Two weeks later another UTI and pneumonia."

Clinicians split the second episode into two categories. Relapse is the same organism returning quickly, usually within about two weeks of finishing treatment, and it points at something structural — urine sitting in the bladder that the antibiotic never reached, a catheter with a film of bacteria on it, a stone, or an organism that was resistant to the drug she was given. Reinfection is a different organism arriving later, and that is where prevention strategies belong.

You can tell them apart, but only if someone cultured her before starting the antibiotic and compares the two reports. That is why the timing and the culture results are worth writing down and carrying to the appointment.

Can treating it be part of why it keeps coming back?

Yes. In older adults, treating bacteria that are not causing illness has been shown to increase the rate of the next infection and make the organism harder to kill.

This is the part almost nobody is told, and it is the most useful thing on this page.

A randomized trial in fifty institutionalized women with a mean age of 83 compared antibiotic therapy for bacteria in the urine against no therapy. The treated group had a higher incidence of reinfection — 1.67 episodes per patient-year against 0.87 — and the organisms that came back were increasingly resistant. Among residents with indwelling catheters, three quarters of the reinfecting organisms in the untreated group were still susceptible to the antibiotic, against roughly a third in the treated group.

A much larger matched cohort of 3,190 adults aged 66 and over looked at standing preventive antibiotics. There was no detectable clinical benefit. There was an increased risk of an emergency visit or hospital admission for urinary infection, sepsis or bloodstream infection, more Clostridioides difficile, and a sharp rise in resistance — a hazard ratio of 1.31 for resistance to any urinary agent, and 5.77 for resistance to the very drug being used to prevent the infections.

That is the mechanism families are never given. The second UTI is sometimes the first one's treatment, arriving on schedule.

The Infectious Diseases Society of America recommends against screening for or treating bacteria in the urine of older long-term care residents who have no urinary symptoms. Its 2019 guideline addresses the specific case where the only change is confusion or a fall: assess for other causes and observe carefully, rather than treat. The American Geriatrics Society carries the same advice on its Choosing Wisely list.

What is actually driving the recurrences?

Mechanics and hormones. Almost nothing on the usual hygiene list has evidence behind it.

The risks with real support are physical:

• Urine left behind after voiding. The bladder that does not empty keeps a reservoir. It is measurable in the office with a bladder scan and it is the most commonly missed cause of a fast relapse.
• Catheters. A long-term indwelling catheter makes bacteriuria near-universal, and the risk rises with every day it stays in. This is the largest modifiable risk on the list.
• Incontinence and time spent in a wet pad.
• Prolapse, which changes how the bladder empties.
• The loss of estrogen after menopause, which changes the vaginal environment and lets uropathogens take hold.

Dementia adds a layer of its own: losing the cue to go, not finding the bathroom in time, resisting toileting help, and being less able to say that something hurts — which is why the first sign is so often behavioral rather than verbal.

Two things families are commonly told do not survive contact with the evidence. The urology guideline on recurrent UTI in women reviewed the behavioral advice — wiping direction, underwear, douching, voiding habits — and found no evidence that any of it changes recurrence. Constipation has a plausible mechanism and is worth treating for its own sake, but the association with urinary infection has been shown mainly in children, not in adults.

Cloudy or strong-smelling urine is the most common reason families ask for a test. The consensus criteria used in long-term care to decide when antibiotics are justified specifically exclude both. Concentrated urine looks dark and smells strong. That is usually dehydration.

What actually reduces recurrence?

Vaginal estrogen and methenamine hippurate have the evidence. The two things most often bought off a shelf do not.

Vaginal estrogen is the strongest non-antibiotic option for postmenopausal women. A placebo-controlled trial in 93 postmenopausal women found 0.5 infections per patient-year on intravaginal estriol against 5.9 on placebo. A Cochrane review found vaginal estrogen reduced infections while oral estrogen did not — across four studies of 2,798 women the oral result was a relative risk of 1.08, effectively nothing. The route is the whole finding. The urology guideline says clinicians should recommend vaginal estrogen for peri- and postmenopausal women with recurrent UTI where there is no contraindication.

Methenamine hippurate is the newer option, and it is a urinary antiseptic rather than an antibiotic, so it does not drive resistance. A 2022 trial found it non-inferior to daily preventive antibiotics — the methenamine group had 0.49 more episodes per person-year, inside the one-episode margin the patient group had set in advance. That trial was in women around fifty, so the more relevant one is the 2025 placebo-controlled trial conducted specifically in women aged seventy and over: roughly a quarter fewer antibiotic treatments for UTI during the six months of treatment.

That same trial found something worth knowing before starting it. After the treatment stopped, the methenamine group had more infections than the placebo group, at nearly twice the rate. It suppresses while it is being taken; it is not a course you finish.

Cranberry is where the headline and the fine print disagree. A 2023 Cochrane review of fifty trials in 8,857 people did find an overall reduction. But in elderly institutionalized men and women specifically — three studies, 1,489 participants — the result was a relative risk of 0.93 with a confidence interval crossing one. No meaningful benefit. The review also notes the evidence does not support use in people with bladder-emptying problems, which describes much of this group.

D-mannose failed outright. A 2024 randomized trial in 598 women found 51.0 percent had a medically attended infection on d-mannose against 55.7 percent on placebo, with no difference in symptoms, consultations or antibiotic use.

More fluids has trial support, but the trial was in women averaging thirty-five years old who were drinking very little to begin with. Pushing fluids into a frail person with incontinence or swallowing trouble has costs of its own. Worth doing if her intake is genuinely low; not a proven fix here.

What should I ask for after the second one?

Ask for a culture before the next antibiotic and a search for the mechanical cause, rather than another prescription on its own.

• A urine culture taken before the antibiotic starts, with the sensitivity report. Same organism as last time points to relapse; a different one points to reinfection. Starting the drug first destroys the information.
• A post-void residual — a bladder scan done in the office that measures what is left after she goes.
• A direct question about the catheter, if she has one: what is it for, and what would have to be true for it to come out.
• A medication review. Anticholinergic bladder drugs, opioids and sedatives all worsen emptying, and all three worsen thinking.
• Whether vaginal estrogen is appropriate, and if not, the reason. Someone will have to apply it, so ask who.
• Whether methenamine hippurate could replace a standing antibiotic, if she is on one or about to be.
• What the plan is if she does not improve on this course — that answer tells you whether anyone is still looking.

And a sudden, abrupt change over hours or days is a separate matter. That is delirium until proved otherwise, and it needs assessment the same day, whatever the cause turns out to be.